Correlations between dysglycemia, markers of oxidative stress and inflammation in diabetic foot patients

Farmacia

Volumn 59, Issue 2, 2011, Pages 216-227

  Virgolici, Bogdana ^a   Mohora, Maria ^a   Radoi, Valentin ^a   Lixandru, Daniela ^a   Stoian, Irina ^a   Gaman, Laura ^a   Coman, Anca ^b   Greabu, Maria ^a   Manuel Y Keenoy, Begona ^c  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b N Paulescu National Institute of Diabetes Nutrition and Metabolic Diseases   (Romania)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

AGE (advanced glycation end products); Diabetic foot; Dysglycaemia; Dyslipidemia; Inflammation

Indexed keywords

ACUTE PHASE PROTEIN; ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; CERULOPLASMIN; FRUCTOSAMINE; GLUCOSE; HAPTOGLOBIN; HEMOGLOBIN A1C; LIPID; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CERULOPLASMIN BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIABETIC FOOT; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; INFLAMMATION; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; URIC ACID BLOOD LEVEL;

EID: 79955752580     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jeffcoate W.J., Harding K.G., Diabetic foot ulcers. The Lancet. 2003, 361, 1545-1551.
2. Richard M.S., Diabetic Ulcers: Treatment & Medication, 2010.
3. Brownlee M., The pathobiology of diabetic complications. A unifying mechanism. Diabetes. 2005, 54, 1615-16244.
4. Hotamisligil G.S., Endoplasmic Reticulum Stress and c-Jun NH2-Terminal Kinase Pathways in Inflammation and Origin of Obesity and Diabetes. Diabetes. 2005, supplement 2, 54, S73-S78.
5. Fonseca V., Clinical Significance of Targeting Postprandial and Fasting Hyperglycemia in Managing Type 2 Diabetes Mellitus. Curr. Med Res Opinion, published online 10/24/2003.
6. Hanefeld M., Fischer S., Julius U., Schulze J., Schwanebeck U., Schmechel H., Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996, 39, 1577-83.
7. Ceriello A., The Management of Post-prandial Glucose. US Endocrinology, 2009, April, Volume 4-Issue II.
8. Friedewald W.T., Levy M., Frederickson D.S., Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preperative ultracentrifuge. Clin Chem. 1972, 18, 499-502.
9. Nielsen F., Mikkelsen B.B., Nielsen J.B., Andersen H.R., Grandjean P., Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of lifestyle factors. Clin Chem. 1997, 43, 1209-1214.
10. Beers R.F., Jr., Sizer I.W., A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem. 1952, 195, 133-140.
11. Habig W.H., Pabst M.J., Jakoby W.B., Glutathione S-Transferases. The First Enyimatic Step in Mercapturic Acid Formation. J Biol Chem. 1974, 249, 7130-7139.
12. Sunderman F.W., Measurement of human serum ceruloplasmin by its pphenylenediamine oxidase activity. Clin. Chem. 1970, 16, 903-910.
13. Mitchel R.E.J., Bimboim H.C., The use of Girard T reagent in a rapid and sensitive method for measuring glyoxal and certain other alfa dicarbonyl compounds, Anal. Biochem. 1977, 81, 47-56.
14. Evans J. L., Goldfine I. D., Maddux B. A., Grodsky G. M., Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?. Diabetes. 2003, 52, 1-8
15. Leiter L. A., Lewanczuk R. Z., Of the Renin-Angiotensin System and Reactive Oxygen Species. Type 2 Diabetes and Angiotensin II Inhibition. Am. J. Hypertension. 2005, 18, 121-128.
16. Monnier L., Colette C., Owens D.R., Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes/Metabolism Reviews. 2009, 25, 393-402.
17. rd, 2008.
18. Marshall W.J., Bangert S.K., Clinical Biochemistry, Metabolic and clinical aspects, second edition, Churchill Livingstone, Elsevier, 2008.
19. Brand-Miller J., Dickinson S., Barclay A., Allman-Farinelli M., Glycemic Index, Glycemic Load, and Thrombogenesis. Seminars in Thrombosis & Haemostasis. Laboratory Diagnostics and Therapy in Thrombosis and Haemostasis: From Bedside to Bench. 2009, 35(1), 111-118.
20. Cheta D., New Insights into Experimental Diabetes. ED. Academiei Romane, 2002.
21. Chien K.L., Chen M.F., Hsu H.C., Chang W.T., Su T.C., Lee Z.T., Hu F.B., Plasma Uric Acid and the Risk of type2 diabetes in Chinese community. Clinical chemistry. 2008, 54, 2, 310-316.
22. Pickup J.C., Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes, Diabetes Care. 2004, 27, 813-823.
23. Ehrenwald E.G.M., Chisolom P.L., Foz, Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J. Clin. Invest. 1994, 93, 1493-1501.
24. Mukhopadhyay C. K., Mazumder B., Lindley P.F., Fox P.L., Identification of the prooxidant site of human ceruloplasmin: a model for oxidative damage by copper bound to protein surfaces. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 11546-11551.
25. Starkebaum, G., Harlan J.M., Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J. Clin. Invest. 1986, 71, 1370-1376.
26. Weigelt C., Rose B., Poschen U., Ziegler D., Friese G., Kempf K., Koenig W., Martin S., Herder C., Immune mediators in patients with acute diabetic foot syndrome, Diabetes Care. 2009, 32, 8, 1491-1496.
27. Haliwell B., Gutteridge J., Free radicals in Biology and Medicine, fourth ed., Claredon Press, Oxford, 2007, 508-514.
28. Stentz F.B., Umpierrez G.E., Cuervo R., Kitabchi A.E., Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004, 53, 2079-2086.
29. Gradinaru D., Mitrea N., et al., Evaluation of serum osteocalcin in elderly patients with type 2 diabetes mellitus, Farmacia, 2009, 57, 3, 331-338
30. Danciulescu R., et. al, Hormonal profile in subjects with metabolic syndrome, Farmacia, 2009, 57, 6, 721-727.